ATE435281T1 - Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung - Google Patents

Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung

Info

Publication number
ATE435281T1
ATE435281T1 AT97936721T AT97936721T ATE435281T1 AT E435281 T1 ATE435281 T1 AT E435281T1 AT 97936721 T AT97936721 T AT 97936721T AT 97936721 T AT97936721 T AT 97936721T AT E435281 T1 ATE435281 T1 AT E435281T1
Authority
AT
Austria
Prior art keywords
cadasil
therapeutic use
diagnostic methods
gene related
gene
Prior art date
Application number
AT97936721T
Other languages
English (en)
Inventor
Elisabeth Tournier-Lasserve
Anne Joutel
Marie-Germaine Bousser
Jean-Francois Bach
Original Assignee
Inst Nat Sante Rech Med
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9609733A external-priority patent/FR2751985B1/fr
Application filed by Inst Nat Sante Rech Med, Assist Publ Hopitaux De Paris filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE435281T1 publication Critical patent/ATE435281T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97936721T 1996-08-01 1997-07-31 Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung ATE435281T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9609733A FR2751985B1 (fr) 1996-08-01 1996-08-01 Gene implique dans le cadasil, methode de diagnostic et application therapeutique
FR9704680A FR2751986B1 (fr) 1996-08-01 1997-04-16 Gene implique dans le cadasil, methode de diagnostic et application therapeutique
PCT/FR1997/001433 WO1998005775A1 (fr) 1996-08-01 1997-07-31 Gene implique dans le cadasil, methode de diagnostic et application therapeutique

Publications (1)

Publication Number Publication Date
ATE435281T1 true ATE435281T1 (de) 2009-07-15

Family

ID=26232895

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97936721T ATE435281T1 (de) 1996-08-01 1997-07-31 Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung

Country Status (9)

Country Link
US (3) US6537775B1 (de)
EP (1) EP0915973B1 (de)
JP (2) JP4463329B2 (de)
AT (1) ATE435281T1 (de)
CA (1) CA2262459C (de)
DE (1) DE69739478D1 (de)
ES (1) ES2328304T3 (de)
FR (1) FR2751986B1 (de)
WO (1) WO1998005775A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751986B1 (fr) * 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
JP2005503792A (ja) * 2001-08-22 2005-02-10 ガラパゴス・ジェノミックス・ナムローゼ・フェンノートシャップ ハイ・スループット・スクリーニングにおいて同定される骨の恒常性のモジュレーター
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
CN1763196B (zh) * 2004-09-13 2010-09-08 首都医科大学宣武医院 基因突变类型及基因测序方法
US7585968B2 (en) * 2005-03-28 2009-09-08 Isis Pharmaceuticals, Inc. Compositions and their uses directed to thymus and activation-regulated chemokine (TARC)
EP2511298B1 (de) 2005-10-31 2019-01-16 Oncomed Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Behandlung von Krebs unter Verwendung von menschlichen FZD Rezeptoren
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP5129149B2 (ja) * 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
WO2007145840A2 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
TW200824707A (en) * 2006-10-19 2008-06-16 Genentech Inc Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
CN101563366B (zh) 2006-10-19 2012-10-03 健泰科生物技术公司 抗notch3激动性抗体及其在制备治疗notch3相关疾病的药物中的用途
AR064388A1 (es) * 2006-12-18 2009-04-01 Genentech Inc Anticuerpos antagonistas anti- notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
US20090208491A1 (en) * 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
JP2010536855A (ja) 2007-08-23 2010-12-02 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク ヒト化Ｎｏｔｃｈ融合タンパク質の組成物および治療方法
WO2009036167A1 (en) * 2007-09-14 2009-03-19 Vanderbilt University Targeting of notch3 receptor function for cancer therapy
MX2011000233A (es) 2008-07-08 2011-05-19 Oncomed Pharm Inc Agentes de union del receptor notch1 y metodos para su uso.
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
KR20110074846A (ko) * 2008-08-22 2011-07-04 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 노치３ 신호전달의 디코이 억제제로서의 인간 노치３ 기반 융합 단백질
DK2331136T3 (en) 2008-09-26 2018-03-05 Oncomed Pharm Inc FRIZZLED BINDING AGENTS AND APPLICATIONS THEREOF
AU2010207073B8 (en) * 2009-01-26 2017-05-18 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Means and methods for modulating NOTCH3 protein expression and/or the coding region of NOTCH3; compositions and use thereof in the treatment of CADASIL
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
EP2523682B1 (de) 2010-01-13 2015-12-16 Oncomed Pharmaceuticals, Inc. Notch1-bindende wirkstoffe und verfahren zu deren verwendung
AU2011235904B2 (en) 2010-04-01 2015-10-08 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2011140295A2 (en) * 2010-05-06 2011-11-10 President And Fellows Of Harvard College Modulators of notch receptor signaling and methods of use thereof
AR088048A1 (es) 2011-10-04 2014-05-07 Univ Columbia Señuelos notch1 humanos
WO2014066328A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
EP2917240A1 (de) 2012-11-07 2015-09-16 Pfizer Inc. Antikörper gegen notch-3 und antikörper-wirkstoff-konjugate
CA2899353A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US20200103419A1 (en) * 2017-03-27 2020-04-02 The Schepens Eye Research Institute, Inc. Blood biomarkers and diagnostic methods for small vessel diseases
WO2018183219A2 (en) * 2017-03-27 2018-10-04 The Schepens Eye Research Institute, Inc. Nucleic acid-based compositions and methods for treating small vessel diseases
WO2018183216A1 (en) 2017-03-27 2018-10-04 The Schepens Eye Research Institute, Inc. Notch3 agonist compositions and methods for treating small vessel diseases
WO2022256396A1 (en) * 2021-06-02 2022-12-08 Regeneron Pharmaceuticals, Inc. Treatment of cerebrovascular disease with neurogenic locus notch homolog protein 3 (notch3) agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116628A1 (en) * 1994-02-28 1995-08-29 Anne Marie Gisele Joutel Method for the diagnosis of cadasil
FR2751986B1 (fr) * 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique

Also Published As

Publication number Publication date
WO1998005775A1 (fr) 1998-02-12
EP0915973A1 (de) 1999-05-19
JP2001500366A (ja) 2001-01-16
JP4463329B2 (ja) 2010-05-19
JP2010042012A (ja) 2010-02-25
US6537775B1 (en) 2003-03-25
CA2262459C (fr) 2013-03-26
ES2328304T3 (es) 2009-11-11
CA2262459A1 (fr) 1998-02-12
US20030186290A1 (en) 2003-10-02
US7138234B2 (en) 2006-11-21
EP0915973B1 (de) 2009-07-01
DE69739478D1 (de) 2009-08-13
FR2751986A1 (fr) 1998-02-06
FR2751986B1 (fr) 1998-12-31
US6995257B1 (en) 2006-02-07

Similar Documents

Publication Publication Date Title
DE69739478D1 (de) Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung
DE69841110D1 (de) Verlängerte cdns, die für sekretierte proteine kodieren
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
CY1105895T1 (el) Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης
DE602004011770D1 (de) Fusionsproteine
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
CY1105398T1 (el) 5΄ ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
DE3856180D1 (de) Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
NO20055309L (no) Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
ATE455185T1 (de) Atypische protein-kinase-c-isoformen bei erkrankungen des nervensystems und krebs
NZ333232A (en) Use of p-aminophenol derivatives (paracetamol) to treat neurodegenerative disease
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
DE602004007924D1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
PT782630E (pt) Gene da doenca poliquistica do rim
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
AU2003224120A1 (en) Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
FI963170A (fi) Menetelmä solujen poikkeavuudesta kärsivien yksilöiden tunnistamiseks i

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties